Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2

Neurology

Volumn 47, Issue 6, 1996, Pages 1531-1534

  Van Oosten, B W ^a   Barkhof, F ^a   Truyen, L ^a   Boringa, J B ^a   Bertelsmann, F W ^a   Von Blomberg, B M E ^a   Woody, J N ^b   Hartung, H P ^c   Polman, C H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTOCOR INC   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SERUM;

EID: 0029751983     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1531     Document Type: Article

References (24)

1. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
2. Rieckmann P, Albrecht M, Kitze B, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994;44:1523-1526.
3. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
4. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995;37:424-435.
5. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954.
6. Robbins DS, Shirazi Y, Drysdale BE, et al. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987;139:2593-2600.
7. Selmaj K, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23: 339-346.
8. Kuroda Y, Shimamoto Y. Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats. J Neuroimmunol 1991;34:159-164.
9. Nataf S, Louboutin JP, Chabannes D, et al. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol Scand 1993;88:97-99.
10. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective inhibitor of T helper 1- but not type 2-associated lymphokine production, prevents induction of experimental allergic encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:1745-1751.
11. Monastra G, Cross AH, Bruni A, Raine CS. Phosphatidylserine, a putative inhibitor of tumor necrosis factor, prevents autoimmune demyelination. Neurology 1994;43:153-163.
12. Ruddle NH, Bergman CM, McGrath KM, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990;172: 1193-1200.
13. Selmaj K, Raine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
14. Baker D, Butler D, Scallon BJ, et al. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994;24: 2040-2048.
15. Genain CP, Roberts T, Davis RL, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995;92:3601-3605.
16. Derkx B, Taminiau J, Radema S, et al. Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 1994;342:173-174.
17. Van Dullemen HM, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
18. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110.
19. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-1127.
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
21. Barkhof F, Scheltens P, Frequin STFM, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs. clinical findings in determining disease activity. AJR 1992; 19:1041-1047.
22. Hartung HP, Reiners K, Archelos JJ, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-193.
23. van Oosten BW, Rep MHG, van Lier RAW, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol 1996;66:49-55.
24. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37: 611-619.